Condition: Hepato Cellular Carcinoma · Sponsor: Ju Dong Yang
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patients may become eligible for a liver transplant. The investigators will also closely watch for side effects from the study treatments. Section 2 has more details.
This description comes directly from the study's public registry record.
Ju Dong Yang, MD · 310-423-6000 · judong.yang@cshs.org
Manaf Alsudaney, MD · 3109677454 · manaf.alsudaney@cshs.org
Always discuss trial participation with your own doctor first.
| Cedars Sinai | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07489976